As a NVAX investor and wannabe vaccine taker (but
Post# of 148177
But now they do NOT work against the BA5 variant.
Novavax's protein-based vaccine should work to some extent on BA5 and new variants because it includes proteins from the unchanging main body of the virus, in addition to the ever-mutating spike protein.
So, why was the U.S. the LAST major company to grant EUA to an American company's more effective vaccine? Why did they slow-walk it until Pfizer and Moderna were granted contracts for additional vaccine, which we know will not work well on BA5?
Kinda obvious, dontcha think?